Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new injection tame the painful lumps of hidradenitis suppurativa?

NCT ID NCT07766005

Disease control Sponsor: Spyre Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial tests whether an investigational medicine called SPY072 can improve hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps and tunnels. About 150 adults with moderate-to-severe HS who are already receiving standard care will be randomly assigned to receive SPY072 or a placebo for 16 weeks. The study will measure how many participants achieve a significant reduction in their HS lesions and will monitor safety and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SPY072, an investigational medicine given as an injection under the skin
What this could lead to
If successful, SPY072 could offer a new treatment option for people with moderate-to-severe hidradenitis suppurativa, potentially reducing painful lumps and improving quality of life.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. The medicine may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening. * Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1. * Total abscess and/or inflammatory nodule count of at least 5 at screening and Day 1. * Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa. Exclusion Criteria: * More than 20 draining tunnels at screening or Day 1. * Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1. * Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa Skin and Connective Tissue Diseases skin disorder sweat gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    12 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site 100

    Bowling Green, Kentucky, 42104, United States

  • Site 101

    Indianapolis, Indiana, 46250, United States

  • Site 102

    New York, New York, 10023, United States

  • Site 103

    Boston, Massachusetts, 02115, United States

  • Site 104

    The Bronx, New York, 10455, United States

  • Site 105

    Dallas, Texas, 75246, United States

  • Site 106

    Mill Creek, Washington, 98012, United States

  • Site 107

    Tyler, Texas, 75703, United States

  • Site 108

    Baton Rouge, Louisiana, 70809, United States

  • Site 109

    Mt. Pleasant, South Carolina, 29464, United States

  • Site 110

    New Orleans, Louisiana, 70115, United States

  • Site 111

    Irvine, California, 92614, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.